Save over 75% on Brand Vemlidy from Europe and over 90% on the generic Vemlidy.
Click here for information on Mylan generics (Immediate availability)
For band Vemlidy, Non-english packaging is often present for European medicines- English label and English insert included. Plan in advance - allow us 7 days to ship this brand name medicine.
According to the European Medicines Agency, brand name Vemlidy originating from Europe is manufactured at the following site(s):Gilead Sciences Ireland UC
IDA Business & Technology Park
Carrigtohill
County Cork
Ireland
Prescription Vemlidy contains the active ingredient tenofovir alafenamide, an antiviral medicine used to treat long term hepatitis B. Vemlidy is used by adults and children 12 years old and older, weighing at least 77 pounds. Vemlidy works by preventing the hepatitis B virus from multiplying.
In a clinical study, 94% of hepatitis patients had very low viral DNA levels after 48 weeks of Vemlidy treatment. This is a very similar result to Viread (tenofovir disoproxil fumarate) however Vemlidy works at a lower dose of tenofovir, leading to fewer side effects in the kidneys and bones.
Side effects with Vemlidy are usually quite mild: headache in 11% of patients, nausea in 6% of patients and tiredness in 6% of patients. For other side effects of Vemlidy, ask your physician or read the package insert.
Do not miss a dose of Vemlidy. If you forget to take Vemlidy and it has been less than 18 hour after you usually take it, take that dose as soon as you remember. If 18 hours has passed since the your missed dose, skip that dose and take your next dose at the regular scheduled time. Do not take double your regular dose of Vemlidy at one time.
In 2019, when comparing Vemlidy to USA Vemlidy coupon price, InsulinHub was found to offer a discount of approximately 30% in Vemlidy savings.
Buy Vemlidy from InsulinHub.com for the best Vemlidy cost.
Information about Vemlidy (Tenofovir Alafenamide)
Vemlidy (Tenofovir Alafenamide) is an antiviral medication used primarily to treat chronic hepatitis B virus (HBV) infection in adults. It belongs to the class of drugs called nucleotide reverse transcriptase inhibitors (NRTIs), which work by inhibiting the replication of the hepatitis B virus, helping to lower viral loads and reduce liver damage caused by the infection. Vemlidy is considered a newer, more potent formulation of tenofovir, offering improved tolerability and fewer side effects compared to older formulations like Tenofovir Disoproxil Fumarate (TDF).
Product Highlights
- Vemlidy is approved for the treatment of chronic hepatitis B virus (HBV) infection in adults, helping to reduce viral load and liver damage.
- Although not commonly used alone for HIV, Vemlidy may be used as part of a combination therapy regimen for HIV-1 infection in some cases.
Key Ingredient
- Tenofovir Alafenamide (TAF)
Key Benefits
- Compared to the older version of tenofovir (Tenofovir Disoproxil Fumarate, TDF), Vemlidy is associated with a lower risk of kidney and bone toxicity, making it a safer option for long-term use.
- The potent formulation of Tenofovir Alafenamide allows for a smaller dose, improving patient compliance and reducing the likelihood of side effects.
- Vemlidy helps reduce HBV viral load and prevents further liver damage, leading to a decrease in complications like cirrhosis and liver cancer.
- Vemlidy is taken just once a day, which improves adherence to the treatment regimen.
Direction of Use
- Vemlidy is taken orally as a tablet.
- The typical dose of Vemlidy for the treatment of chronic hepatitis B is 25 mg once daily. This should be taken with food to help absorption.
- It’s important to take Vemlidy regularly at the same time each day for optimal effectiveness.
- Adherence to the full treatment regimen is crucial for the effectiveness of the drug. Missing doses can result in increased viral replication and potential resistance.
Safety Concerns
- Even though Vemlidy has a lower risk of kidney toxicity than older tenofovir formulations, it can still cause kidney problems in some individuals, especially those with pre-existing kidney conditions. Kidney function should be monitored regularly during treatment.
- Long-term use of tenofovir (even the Alafenamide version) can impact bone mineral density. Patients should be monitored for signs of bone loss, and calcium or vitamin D supplements may be recommended.
- As with other NRTIs, Vemlidy carries a rare risk of lactic acidosis (a buildup of lactic acid in the blood) and hepatomegaly (enlargement of the liver), which can be serious. Symptoms to watch for include muscle weakness, pain, and difficulty breathing.
- If treatment with Vemlidy is stopped, there’s a risk of reactivation of hepatitis B. This can be severe, so it is important to discuss any changes in treatment with a healthcare provider.
- The safety of Vemlidy during pregnancy has not been fully established. It should only be used during pregnancy if the benefits outweigh the risks, and it’s not recommended while breastfeeding.
Avoid Vemlidy (Tenofovir Alafenamide) If
- If you have severe kidney disease or impairment (e.g., creatinine clearance below 15 mL/min), Vemlidy should be avoided as it may worsen kidney function.
- If you have a known allergy or hypersensitivity to Tenofovir Alafenamide or any component of Vemlidy, you should not use this medication.
- While Vemlidy can be used in HIV-positive patients as part of a combination regimen, it should not be used as the sole therapy for patients with both HBV and HIV infections unless part of a combination regimen specifically designed for both viruses.
- If you have liver conditions like cirrhosis or severe liver damage, you should use Vemlidy with caution, and liver function should be regularly monitored.
